Citius Pharmaceuticals (CTXR) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 28, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 10-Q for Q3 FY2026, filed Aug 14, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the CTXR SEC filings page.
This page shows Citius Pharmaceuticals Inc. (CTXR) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Losses remain persistent while rising liabilities and inventory make financing structure, rather than sales growth, the clearest operating constraint.
From FY2024 to FY2025, the net loss narrowed from$39.1M to$37.4M while operating cash outflow narrowed from$28.2M to$26.6M , so accounting losses and cash consumption moved in the same direction. Meanwhile, liabilities rose25.5% while equity fell3.6% , indicating that the balance sheet is becoming more liability-funded even as annual losses continue.
The current ratio improved from 0.4x to 0.6x, yet remained below parity, meaning current assets still did not cover current liabilities at year-end. The reported liquidity measure equaled 1.9 months of the latest annual operating outflow, describing limited short-term coverage without forecasting future operations.
Inventory increased
Financial Health Signals
Citius Pharmaceuticals Inc. does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.
Citius Pharmaceuticals Inc. passes 3 of 6 computable financial strength tests (3 of the nine could not be computed from available data). 2 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass.
Citius Pharmaceuticals Inc. reported a net loss of $37.4M while operations used $26.6M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Citius Pharmaceuticals Inc. reported an operating loss of $38.5M against $50K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.
Key Financial Metrics
Earnings & Revenue
Citius Pharmaceuticals Inc. generated $1.5M in revenue in Q3 2026. Against the prior quarter it is down 10.4%.
Citius Pharmaceuticals Inc. reported a net loss of $8.9M in Q3 2026. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.
Citius Pharmaceuticals Inc. earned -$0.34 per diluted share (EPS) in Q3 2026. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.
Not reported for Q3 2026.
Cash & Balance Sheet
Citius Pharmaceuticals Inc. held $17.0M in cash as of Q3 2026; no long-term debt figure is on record for that period.
Not reported for Q3 2026.
Not reported for Q3 2026.
Margins & Returns
Citius Pharmaceuticals Inc.'s gross margin was 67.1% in Q3 2026, indicating the percentage of revenue retained after direct costs. Against the prior quarter it is down 13.2 percentage points.
Citius Pharmaceuticals Inc.'s quarterly ROE was -13.3% in Q3 2026: one quarter's net income over shareholder equity, not annualized. This is up 0.2 percentage points from the same quarter a year earlier. Against the prior quarter it is up 21.2 percentage points.
Not shown for Q3 2026: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Not shown for Q3 2026: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Capital Allocation
Citius Pharmaceuticals Inc. invested $1.1M in research and development in Q3 2026. This represents a decrease of 35.0% from the same quarter a year earlier. Against the prior quarter it is down 35.5%.
Not reported for Q3 2026.
Not reported for Q3 2026.
CTXR Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1.5M | $1.7M | $3.9M | N/A | N/A | N/A | N/A | N/A |
| Cost of Revenue | $492K | $329K | $789K | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | $1.0M | $1.3M | $3.2M | N/A | N/A | N/A | N/A | N/A |
| R&D Expenses | $1.1M-35.0% | $1.6M-56.6% | $1.6M-24.8% | N/A | $1.6M-41.3% | $3.8M+4.5% | $2.1M-18.9% | N/A |
| SG&A Expenses | $6.1M+38.3% | $26.4M+450.7% | $5.7M+6.2% | N/A | $4.4M-7.5% | $4.8M+11.8% | $5.4M+47.2% | N/A |
| Operating Income | -$11.7Mn/m | -$32.2Mn/m | -$9.0Mn/m | N/A | -$8.8Mn/m | -$11.3Mn/m | -$10.0Mn/m | N/A |
| Interest Expense | $198K+1623.6% | $33K | $156K | N/A | $12K | N/A | N/A | N/A |
| Income Tax | -$107K-140.6% | -$231K-187.5% | $264K0.0% | N/A | $264K+83.5% | $264K+83.5% | $264K+83.5% | N/A |
| Net Income | -$8.9Mn/m | -$21.2Mn/m | -$8.2Mn/m | N/A | -$8.8Mn/m | -$11.5Mn/m | -$10.3M-211.4% | N/A |
| EPS (Basic) | -$0.34 | -$0.95 | -$0.38 | -$0.11 | -$0.80 | -$1.27 | -$1.30 | -$1.60 |
| EPS (Diluted) | -$0.34 | -$0.95 | -$0.38 | -$0.11 | -$0.80 | -$1.27 | -$1.30 | -$1.60 |
| Diluted Shares (Avg) | 26M | 22M | 21M | N/A | 11M | 9M | 7M | N/A |
Not reported in any period shown, so not listed: EBITDA.
CTXR Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $142.3M+11.4% | $132.5M+9.1% | $140.4M+16.3% | $130.9M+12.2% | $127.7M+31.5% | $121.5M+33.9% | $120.7M+23.9% | $116.7M+12.6% |
| Current Assets | $43.3M+76.1% | $31.7M+72.4% | $37.9M+107.0% | $27.9M+96.4% | $24.6M-12.1% | $18.4M-14.8% | $18.3M-35.0% | $14.2M-58.6% |
| Cash & Equivalents | $17.0M+179.3% | $4.6M+17280.4% | $7.7M+601.9% | $4.3M+30.8% | $6.1M-66.0% | $26K-99.8% | $1.1M-94.6% | $3.3M-87.7% |
| Short-Term Investments | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m |
| Inventory | $22.6M+31.5% | $22.7M+47.7% | $22.6M+57.4% | $22.3M+169.5% | $17.2M | $15.3M | $14.4M | $8.3M |
| Accounts Receivable | $686K | $1.1M | $4.0M | N/A | N/A | N/A | N/A | N/A |
| Long-Term Investments | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m |
| Goodwill | $9.3M0.0% | $9.3M0.0% | $9.3M0.0% | $9.3M0.0% | $9.3M0.0% | $9.3M0.0% | $9.3M0.0% | $9.3M0.0% |
| Total Liabilities | $66.3M+10.4% | $63.5M+9.6% | $46.9M-9.4% | $53.4M+25.5% | $60.1M+456.3% | $57.9M+438.9% | $51.8M+329.2% | $42.5M+249.4% |
| Current Liabilities | $51.6M-0.4% | $55.0M+10.3% | $38.2M-14.7% | $44.9M+25.4% | $51.8M+1148.6% | $49.9M+1095.1% | $44.8M+703.1% | $35.8M+519.7% |
| Non-Current Liabilities | $14.7M+77.6% | $8.4M+5.1% | $8.7M+24.9% | $8.5M+26.1% | $8.3M+24.3% | $8.0M+22.2% | $7.0M+7.6% | $6.7M+5.2% |
| Total Equity | $66.6M+2.4% | $61.5M+1.5% | $80.0M+22.2% | $67.6M-3.6% | $65.1M-24.1% | $60.7M-23.6% | $65.4M-22.8% | $70.1M-22.8% |
| Retained Earnings | -$277.1Mn/m | -$268.3Mn/m | -$247.0Mn/m | -$238.8Mn/m | -$230.8Mn/m | -$222.1Mn/m | -$211.1Mn/m | -$201.4Mn/m |
Not reported in any period shown, so not listed: Long-Term Debt.
CTXR Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$8.7Mn/m | -$1.3Mn/m | -$13.0Mn/m | -$11.9Mn/m | -$5.4Mn/m | -$4.5Mn/m | -$4.7Mn/m | -$5.9Mn/m |
| Depreciation & Amortization | N/A | N/A | N/A | N/A | N/A | N/A | N/A | $0-100.0% |
| Stock-Based Compensation | $3.8M+40.1% | $3.8M+40.2% | $4.3M+69.5% | N/A | $2.7M-11.2% | $2.7M-12.2% | $2.5M-17.4% | N/A |
| Investing Cash Flow | -$2.0M | -$600K | -$4.4M | N/A | N/A | N/A | N/A | N/A |
| Financing Cash Flow | $23.1M+101.4% | -$1.2M-135.5% | $20.9M+711.1% | $15.8Mn/m | $11.5M | $3.5M | $2.6M | -$3.7Mn/m |
Not reported in any period shown, so not listed: Capital Expenditures, Free Cash Flow, Dividends Paid, Share Buybacks.
CTXR Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 67.1% | 80.3% | 80.0% | N/A | N/A | N/A | N/A | N/A |
| Operating Margin | -785.4% | -1931.0% | -228.7% | N/A | N/A | N/A | N/A | N/A |
| Net Margin | -593.3% | -1273.4% | -208.4% | N/A | N/A | N/A | N/A | N/A |
| Return on Equity | -13.3%+0.2pp | -34.5%-15.5pp | -10.3%+5.4pp | N/A | -13.5%-1.2pp | -19.0%-8.2pp | -15.7%-26.6pp | N/A |
| Return on Assets | -6.2%+0.6pp | -16.0%-6.5pp | -5.9%+2.7pp | N/A | -6.9%+4.0pp | -9.5%-0.1pp | -8.5%-18.0pp | N/A |
| Current Ratio | 0.84+0.4x | 0.58+0.2x | 0.99+0.6x | 0.62+0.2x | 0.47-6.3x | 0.37-4.8x | 0.41-4.6x | 0.40-5.6x |
| Liabilities-to-Equity | 1.00+0.1x | 1.03+0.1x | 0.59-0.2x | 0.79+0.2x | 0.92+0.8x | 0.95+0.8x | 0.79+0.6x | 0.61+0.5x |
| Asset Turnover | 0.01 | 0.01 | 0.03 | N/A | N/A | N/A | N/A | N/A |
Not reported in any period shown, so not listed: Debt-to-Equity, FCF Margin.
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin.
Note: The current ratio is below 1.0 (0.62), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| Citius Pharmaceuticals Inc. CTXR | FY2025 | N/A | -$37.4M | N/A | $14.9M | — |
| Lisata Therapeutics, Inc. LSTA | FY2025 | $170K | -$16.6M | N/A | $11.0M | — |
| Q32 Bio Inc. QTTB | FY2025 | $53.7M | $29.8M | 55.5% | $259.3M | 46/100 |
| Rein Therapeutics, Inc. RNTX | FY2025 | $0 | -$49.9M | N/A | $60.7M | — |
Where Citius Pharmaceuticals Inc. Ranks
Frequently Asked Questions
Is Citius Pharmaceuticals Inc. profitable?
No, Citius Pharmaceuticals Inc. (CTXR) reported a net loss of $37.4M in fiscal year 2025.
What is Citius Pharmaceuticals Inc.'s return on equity (ROE)?
Citius Pharmaceuticals Inc. (CTXR) has a return on equity of -55.4% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Citius Pharmaceuticals Inc.'s operating cash flow?
Citius Pharmaceuticals Inc. (CTXR) recorded an outflow of $26.6M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are Citius Pharmaceuticals Inc.'s total assets?
Citius Pharmaceuticals Inc. (CTXR) had $130.9M in total assets as of fiscal year 2025, including both current and long-term assets.
How much does Citius Pharmaceuticals Inc. spend on research and development?
Citius Pharmaceuticals Inc. (CTXR) invested $9.2M in research and development during fiscal year 2025.
What is Citius Pharmaceuticals Inc.'s current ratio?
Citius Pharmaceuticals Inc. (CTXR) had a current ratio of 0.62 as of fiscal year 2025, which is below 1.0, which may suggest potential liquidity concerns.
What is Citius Pharmaceuticals Inc.'s liabilities-to-equity ratio?
Citius Pharmaceuticals Inc. (CTXR) had a liabilities-to-equity ratio of 0.79 as of fiscal year 2025, which is total liabilities divided by total shareholder equity. Total liabilities counts every obligation on the balance sheet (payables, deposits, insurance reserves and deferred taxes as well as borrowings), so this ratio usually runs well above debt-to-equity. No debt-to-equity ratio is shown for fiscal year 2025, because the filing data we hold for that year carries no long-term debt figure.
What is Citius Pharmaceuticals Inc.'s return on assets (ROA)?
Citius Pharmaceuticals Inc. (CTXR) had a return on assets of -28.6% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Citius Pharmaceuticals Inc.'s P/E ratio?
Citius Pharmaceuticals Inc. (CTXR) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (FY2025). The market capitalization is $14.9M as of Oct 28, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is Citius Pharmaceuticals Inc.'s price-to-sales ratio?
Citius Pharmaceuticals Inc. (CTXR) has no price-to-sales ratio at the moment: no revenue reported. The market capitalization is $14.9M as of Oct 28, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
How does Citius Pharmaceuticals Inc.'s liquidity compare with its operating cash outflow?
At the end of fiscal year 2025, Citius Pharmaceuticals Inc. (CTXR) held $4.3M in cash, cash equivalents and investments, and reported an operating cash outflow of $26.6M over that year. Dividing the one by the other, the reported balance equals about 2 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
What is Citius Pharmaceuticals Inc.'s Piotroski F-Score?
Citius Pharmaceuticals Inc. (CTXR) has a Piotroski F-Score of 3 out of 6 computable signals; 3 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Citius Pharmaceuticals Inc.'s earnings high quality?
Citius Pharmaceuticals Inc. (CTXR) reported a net loss of $37.4M while operations used $26.6M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Citius Pharmaceuticals Inc. cover its interest payments?
Citius Pharmaceuticals Inc. (CTXR) reported an operating loss of $38.5M against $50K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.